These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 31995677)

  • 1. A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia.
    Caroff SN; Citrome L; Meyer J; Sajatovic M; Goldberg JF; Jain R; Lundt L; Lindenmayer JP; McEvoy JP; McIntyre RS; Tohen M; Ketter TA
    J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
    Citrome LL
    J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN; Aggarwal S; Yonan C
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.
    Salem H; Pigott T; Zhang XY; Zeni CP; Teixeira AL
    Expert Rev Neurother; 2017 Sep; 17(9):883-894. PubMed ID: 28750568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.
    Correll CU; Kane JM; Citrome LL
    J Clin Psychiatry; 2017; 78(8):1136-1147. PubMed ID: 29022654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive Dyskinesia: Treatment Update.
    Arya D; Khan T; Margolius AJ; Fernandez HH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel.
    Page AT; Potter K; Clifford R; McLachlan AJ; Etherton-Beer C
    Intern Med J; 2016 Oct; 46(10):1189-1197. PubMed ID: 27527376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic-induced tardive dyskinesia: update on epidemiology and management.
    Widschwendter CG; Hofer A
    Curr Opin Psychiatry; 2019 May; 32(3):179-184. PubMed ID: 30720484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological treatment of tardive dyskinesia: recent developments.
    Caroff SN; Campbell EC; Carroll B
    Expert Rev Neurother; 2017 Sep; 17(9):871-881. PubMed ID: 28727483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
    Citrome L; Saklad SR
    J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H; Henchcliffe C
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia.
    Jackson R; Brams MN; Carlozzi NE; Citrome L; Fritz NE; Hoberg AR; Isaacson SH; Kane JM; Kumar R
    J Clin Psychiatry; 2022 Nov; 84(1):. PubMed ID: 36449471
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Tardive Dyskinesia.
    Bashir HH; Jankovic J
    Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Bone Marrow Concentrate to Treat Pain and Musculoskeletal Disorders: An Academic Delphi Investigation.
    Centeno CJ; Jerome MA; Pastoriza SM; Shapiro S; Mautner K; Malanga GA; DePalma MJ; Mason RA; Stemper I; Dodson E
    Pain Physician; 2021 May; 24(3):263-273. PubMed ID: 33988946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.